The duration of a course of capmatinib treatment

Capmatinib (Capmatinib) is a targeted therapy for patients with non-small cell lung cancer (NSCLC) with skip mutations in exon 14 of MET. Under normal circumstances, the standard treatment plan recommends that patients take 400 mg orally twice a day, and there is no fixed limit on the specific time of a course of treatment.

In clinical practice, the length of a patient's treatment course will be affected by the assessment of treatment effectiveness. After initial treatment, doctors usually order imaging evaluations within 2 to 3 months to see if the tumor has shrunk or if the disease has remained stable. If the condition is effectively controlled and the patient is able to tolerate the treatment, the course of treatment may be extended for months or even years. This personalized treatment design helps to optimize the patient's treatment effect to the greatest extent.

As a targeted drug, capmatinib is often used throughout the entire treatment process. For some patients, long-term medication may be needed to control tumor growth, a treatment similar to the management of a chronic disease. Treatment will continue as long as the patient tolerates the drug well and the disease does not progress. Long-term use of capmatinib can significantly extend progression-free survival (PFS) for some patients.

However, if a patient develops serious side effects while taking the medication, the doctor may consider temporarily interrupting treatment or adjusting the medication dose. In some cases, if a patient's disease progresses or becomes resistant to the drug, treatment may be discontinued and switched to another treatment regimen. Therefore, the length of capmatinib treatment will vary among patients.

Clinical trial data show that the duration of capmatinib treatment is often closely related to time to disease progression (TTP) and progression-free survival (PFS). For example, in one pivotal study, patients were treated for a median of 5.5 months, but some patients were treated for longer than 12 months. It can be seen that the length of treatment will vary depending on factors such as the patient's individual response, genetic mutation characteristics, and treatment tolerance.

xa0

Reference materials

FDA Capmatinib Approval Information -

https://www.fda.gov/drugs/drug-approvals-and-databases/tabrecta-capmatinib